MedTrace Logo

Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19

NCT04456361 · Status: ACTIVE_NOT_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-03-06

No results posted yet for this study

Summary

This is a pilot phase, open label, non-randomized study for the treatment of ARDS in patients infected with COVID-19. Subjects will be enrolled and treated with one dose of mesenchymal stem cells and follow-up will occur 90 days post-treatment.

Conditions

Interventions

BIOLOGICAL

Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords

Mesenchymal Stem Cells as a single-dose therapy via IV infusion at a dose of 1 X 10 8 cells.

Sponsors & Collaborators

  • Instituto de Medicina Regenerativa

    lead INDUSTRY

Principal Investigators

  • Jesus Perez · Instituto de Medicina Regenerativa

  • Juan Parcero · Instituto de Medicina Regenerativa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2025-02-15
Completion
2025-11-15

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04456361 on ClinicalTrials.gov